Increased THEMIS First Exon Usage in CD4+ T-Cells Is Associated with a Genotype that Is Protective against Multiple Sclerosis

Open Access

Peer-reviewed

Research Article

Jessica L. Davies ,

* E-mail: jessicaldavies6@gmail.com

Affiliation Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom

http://orcid.org/0000-0002-8888-1441

⨯
Sara Thompson,

Affiliation Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
⨯
Harpreet Kaur-Sandhu,

Affiliation Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
⨯
Stephen Sawcer,

Affiliation Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
⨯
Alasdair Coles,

Affiliation Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
⨯
Maria Ban,

Affiliation Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
⨯
Joanne Jones

Affiliation Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
⨯

Reader Comments (0)

T cells
Is the Subject Area "T cells" applicable to this article?

Thanks for your feedback.
Single nucleotide polymorphisms
Is the Subject Area "Single nucleotide polymorphisms" applicable to this article?

Thanks for your feedback.
Cytotoxic T cells
Is the Subject Area "Cytotoxic T cells" applicable to this article?

Thanks for your feedback.
Transcription factors
Is the Subject Area "Transcription factors" applicable to this article?

Thanks for your feedback.
Multiple sclerosis
Is the Subject Area "Multiple sclerosis" applicable to this article?

Thanks for your feedback.
Genome-wide association studies
Is the Subject Area "Genome-wide association studies" applicable to this article?

Thanks for your feedback.
Gene expression
Is the Subject Area "Gene expression" applicable to this article?

Thanks for your feedback.
Medical risk factors
Is the Subject Area "Medical risk factors" applicable to this article?

Thanks for your feedback.